Skip to content

myC – my Cancer my Concern Infographics

What is the myC Project?

Launched in 2022, myC (my Cancer my Concern) is a Cancer Patients Europe (CPE) initiative that aims to raise awareness of the benefits and values of genomic testing in cancer, educate patients and stakeholders, and improve accessibility to genomic testing across Europe. TheGenomics and Breast Cancer European Patients Survey is the first step of the myC initiative and part of CPE’s broader goal to improve the management of cancer for patients across Europe.

Read more

Some of us will benefit from genomic testing.
All of us can help.

Survey Infographic Topline results

DOWNLOAD IN PDF

KEY FINDING

4 out of 5 breast cancer patients eligible for genomic testing were not told it was available to them.

1,383
respondents completed the survey in 5 countries.

50%
eligible for genomic testing

83%
with breast cancer

65%
aged 40-59

A LACK OF AWARENESS OF GENOMIC TESTING

59%
had not heard about personalised or precision medicine.

55%
did not know the difference between genetic and genomic testing.

63%
had not heard about genomic testing in cancer.

Of breast cancer patients eligible for genomic testing…

84%
did not have enough information to make a decision.
75%
did not take a genomic test.

PATIENTS NEED MORE MEDICAL INFORMATION

49%
either did not find or only sometimes found the information they needed in a way that they could understand.

Medical professionals and the internet were top sources of medical information.

During their breast cancer journey, patients would have liked more information on:

Type of cancer
34%
Additional testing
37%
Treatment options
38%
Long-term treatment effects
55%

Survey Infographic Topline results – France

DOWNLOAD IN PDF

KEY FINDING – FRANCE

4 out of 5 breast cancer patients eligible for genomic testing were not told it was available to them.

633
respondents completed the survey in France.

94%
with breast cancer

50%
eligible for genomic testing

67%
aged 40-59

A LACK OF AWARENESS OF GENOMIC TESTING

68%
had not heard about personalised or precision medicine.

51%
did not know the difference between genetic and genomic testing.

67%
had not heard about genomic testing in cancer.

Of breast cancer patients eligible for genomic testing…

88%
did not have enough information to make a decision.
81%
did not take a genomic test.

PATIENTS NEED MORE MEDICAL INFORMATION

47%
either did not find or only sometimes found the information they needed in a way that they could understand.

Medical professionals and the internet were top sources of medical information.

During their breast cancer journey, patients would have liked more information on:

Type of cancer
33%
Additional testing
35%
Treatment options
36%
Long-term treatment effects
58%

Survey Infographic Topline results – Germany

DOWNLOAD IN PDF

KEY FINDING – GERMANY

4 out of 5 breast cancer patients eligible for genomic testing were not told it was available to them.

249
respondents completed the survey in Germany.

81%
with breast cancer

54%
eligible for genomic testing

69%
aged 40-59

A LACK OF AWARENESS OF GENOMIC TESTING

57%
had not heard about personalised or precision medicine.

60%
did not know the difference between genetic and genomic testing.

67%
had not heard about genomic testing in cancer.

Of breast cancer patients eligible for genomic testing…

81%
did not have enough information to make a decision.
65%
did not take a genomic test.

PATIENTS NEED MORE MEDICAL INFORMATION

53%
either did not find or only sometimes found the information they needed in a way that they could understand.

Medical professionals and the internet were top sources of medical information.

During their breast cancer journey, patients would have liked more information on:

Type of cancer
32%
Additional testing
46%
Treatment options
52%
Long-term treatment effects
56%

Survey Infographic Topline results – Italy

DOWNLOAD IN PDF

KEY FINDING – ITALY

3 out of 5 breast cancer patients eligible for genomic testing were not told it was available to them.

146
respondents completed the survey in Italy.

64%
with breast cancer

41%
eligible for genomic testing

65%
aged 40-59

A LACK OF AWARENESS OF GENOMIC TESTING

47%
had not heard about personalised or precision medicine.

43%
did not know the difference between genetic and genomic testing.

43%
had not heard about genomic testing in cancer.

Of breast cancer patients eligible for genomic testing…

68%
did not have enough information to make a decision.
58%
did not take a genomic test.

PATIENTS NEED MORE MEDICAL INFORMATION

54%
either did not find or only sometimes found the information they needed in a way that they could understand.

Medical professionals and the internet were top sources of medical information.

During their breast cancer journey, patients would have liked more information on:

Type of cancer
26%
Additional testing
36%
Treatment options
30%
Long-term treatment effects
45%

Survey Infographic Topline results – Spain

DOWNLOAD IN PDF

KEY FINDING – SPAIN

4 out of 5 breast cancer patients eligible for genomic testing were not told it was available to them.

146
respondents completed the survey in Spain.

77%
with breast cancer

41%
eligible for genomic testing

60%
aged 40-59

A LACK OF AWARENESS OF GENOMIC TESTING

35%
had not heard about personalised or precision medicine.

55%
did not know the difference between genetic and genomic testing.

63%
had not heard about genomic testing in cancer.

Of breast cancer patients eligible for genomic testing…

93%
did not have enough information to make a decision.
76%
did not take a genomic test.

PATIENTS NEED MORE MEDICAL INFORMATION

49%
either did not find or only sometimes found the information they needed in a way that they could understand.

Medical professionals and the internet were top sources of medical information.

During their breast cancer journey, patients would have liked more information on:

Type of cancer
39%
Additional testing
21%
Treatment options
40%
Long-term treatment effects
50%

Survey Infographic Topline results – United Kingdom

DOWNLOAD IN PDF

KEY FINDING – UK

4 out of 5 breast cancer patients eligible for genomic testing were not told it was available to them.

209
respondents completed the survey in UK.

70%
with breast cancer

54%
eligible for genomic testing

55%
aged 40-59

A LACK OF AWARENESS OF GENOMIC TESTING

60%
had not heard about personalised or precision medicine.

60%
did not know the difference between genetic and genomic testing.

60%
had not heard about genomic testing in cancer.

Of breast cancer patients eligible for genomic testing…

78%
did not have enough information to make a decision.
77%
did not take a genomic test.

PATIENTS NEED MORE MEDICAL INFORMATION

45%
either did not find or only sometimes found the information they needed in a way that they could understand.

Medical professionals and the internet were top sources of medical information.

During their breast cancer journey, patients would have liked more information on:

Type of cancer
35%
Additional testing
50%
Treatment options
36%
Long-term treatment effects
56%